Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Hematologic Malignancies
Interventions: StemEx; Biological
Lead sponsor: Loyola University; Other
Eligibility: 55 Years to 73 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Genitourinary Syndrome of Menopause (GSM)
Interventions: Vaginal estrogen tablet, Via Solv Wellness (Hyaluronic Acid Therapy); Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 45 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Self-efficacy
Interventions: Motivational interviewing (MI); Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ipilimumab, Vaccine, FOLFIRINOX; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri

Conditions: Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Biospecimen Collection, Cholestyramine, Computed Tomography, Diagnostic Imaging, Gemcitabine, Leflunomide, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Postoperative Pain
Interventions: Q8003 (morphine sulfate and oxycodone hydrochloride), Placebo; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more

Conditions: Acute Low Back Pain
Interventions: Combination drug (Acetaminophen + Tramadol), Placebo; Drug
Lead sponsor: Labopharm Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Montgomery, Alabama • Centennial, Colorado • Hialeah, Florida + 14 more

Conditions: Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
Interventions: Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, Selumetinib Sulfate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: docetaxel & capecitabine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diffuse Large B Cell Lymphoma, Transformed Lymphoma
Interventions: Handgrip strength test, Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR), Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS), Neuropsychological Assessment - Color Trails, Neuropsychological Assessment -Stroop Color and Word Test, Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Quality of Life (EQ-5D-5L) Questionnaire, PROMIS Cognitive Function 4a Questionnaire, Comprehensive Score for Financial Toxicity (COST) measure; Other · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
Interventions: Epidiolex; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Photosensitive Epilepsy
Interventions: Fenfluramine Hydrochloride; Drug
Lead sponsor: Elizabeth Anne Thiele; Other
Eligibility: 4 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Central Serous Chorioretinopathy
Interventions: Photodynamic Therapy with Verteporfin, verteporfin; Procedure · Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Amphetamine Dependence
Interventions: Mirtazapine, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colorectal Cancer
Interventions: celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 826
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more

Conditions: Therapy, Exercise
Interventions: Isometric exercises, Eccentric exercises; Other
Lead sponsor: Carrick Institute for Graduate Studies; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cape Canaveral, Florida

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more

Conditions: Familial Amyotrophic Lateral Sclerosis
Interventions: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days; Drug
Lead sponsor: Edward Kasaraskis; Other
Eligibility: 20 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions: VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large); Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid-related Disorders
Interventions: Buprenorphine, Morphine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Pegfilgrastim (Neulasta), Apheresis; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medication Adherence, Hypertension
Interventions: My Interprofessional Care team for Adherence and Research Engagement (MI-CARE); Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Hemophilia A
Interventions: Moroctocog alfa (AF-CC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 15 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 7
States / cities: Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Stem Cell Transplantation
Interventions: Auto-hMSCs, Allo-hMSCs; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miami, Florida • Baltimore, Maryland

Search by objective public record fields.

Umbilical Cord Transplantation for the Elderly Population

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

Motivational Interviewing Intervention for Intimate Partner Violence

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Buprenorphine's Dose Response Curve

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

My Interprofessional Care Team for Adherence and Research Engagement Disparities

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)